Apotheca Biosciences (PCFP) R & D Focuses on Opioid Crisis, a National Public Health Emergency

Seattle, WA , April 17, 2018 (GLOBE NEWSWIRE) — Apotheca Biosciences (PCFP), a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry announces today that the company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. Apotheca announces today that the Company’s 2018 R & D goals focused on products and technologies to address opioid crisis.

Share this post